ArticleCancer immunology research2016
Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance.
Article in Cancer immunology research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Targeting PP2A in cancer: an underrated option.Journal of experimental & clinical cancer research : CR · 2025Review
- Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma.PLoS genetics · 2025Article
- PD-1 is requisite for skin TNature immunology · 2025Article
- Urine scRNAseq reveals new insights into the bladder tumor immune microenvironment.The Journal of experimental medicine · 2024Article
- MAdCAM-1 co-stimulation combined with retinoic acid and TGF-β induces blood CD8Mucosal immunology · 2024Article
- CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process.Cancer gene therapy · 2023Article
- Abnormally primed CD8 T cells: The Achilles' heel of CHB.Frontiers in immunology · 2023Review
- Responsiveness to interleukin-15 therapy is shared between tissue-resident and circulating memory CD8Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Single-cell profiling defines the prognostic benefit of CD39Communications biology · 2021Article
- Review
- Tumor-infiltrating CD8Drug discovery today · 2021Review
- Expression pattern, regulation, and clinical significance of TOX in breast cancer.Cancer immunology, immunotherapy : CII · 2021Article
- Tissue-resident memory-like T cells in tumor immunity: Clinical implications.Seminars in immunology · 2020Review
- Checkpoint inhibitor blockade and epigenetic reprogrammability in CD8Therapeutic advances in vaccines and immunotherapy · 2020Review
- Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.Cancer immunology research · 2019Article
- miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8Nature communications · 2019Article
- Striking a Balance-Cellular and Molecular Drivers of Memory T Cell Development and Responses to Chronic Stimulation.Frontiers in immunology · 2019Review
- Newcastle disease virus co-expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy.Cancer science · 2018Article
- Runx3 programs CD8Nature · 2017Article
- Metabolism shapes the tumor microenvironment.Current opinion in cell biology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Despite clinical potential and recent advances, durable immunotherapeutic ablation of solid tumors is not routinely achieved. IL15 expands natural killer cell (NK), natural killer T cell (NKT) and CD8(+) T-cell numbers and engages the cytotoxic program, and thus is under evaluation for potentiation of cancer immunotherapy. We found that short-term therapy with IL15 bound to soluble IL15 receptor α-Fc (IL15cx; a form of IL15 with increased half-life and activity) was ineffective in the treatment of autochthonous PyMT murine mammary tumors, despite abundant CD8(+) T-cell infiltration. Probing of this poor responsiveness revealed that IL15cx only weakly activated intratumoral CD8(+) T cells, even though cells in the lung and spleen were activated and dramatically expanded. Tumor-infiltrating CD8(+) T cells exhibited cell-extrinsic and cell-intrinsic resistance to IL15. Our data showed that in the case of persistent viral or tumor antigen, single-agent systemic IL15cx treatment primarily expanded antigen-irrelevant or extratumoral CD8(+) T cells. We identified exhaustion, tissue-resident memory, and tumor-specific molecules expressed in tumor-infiltrating CD8(+) T cells, which may allow therapeutic targeting or programming of specific subsets to evade loss of function and cytokine resistance, and, in turn, increase the efficacy of IL2/15 adjuvant cytokine therapy. Cancer Immunol Res; 4(9); 799-811. ©2016 AACR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.